ProMetic's PBI-1402 Abstract Available Through American Society of Hematology's Web Site

MONTREAL, QUEBEC -- (MARKET WIRE) -- 11/13/07 -- ProMetic Life Sciences Inc. (TSX: PLI) ("ProMetic") announced today that ProMetic's abstract on its PBI-1402 Phase II clinical trial in patients with chemotherapy-induced anemia ("CIA") is now available on the American Society of Hematology's ("ASH") Web site under the heading "Annual Meeting Abstracts" More substantive information will be reported in conjunction with a poster to be presented at ASH's annual meeting on December 9, 2007. About PBI-1402 PBI-1402 is an orally active compound being developed to treat different types of anemia, such as CIA. ProMetic has recently expanded its clinical program for PBI-1402 for treatment of patients with cancer-related anemia, such as myelodysplastic syndrome, a condition often referred to as "pre-leukemia". Clinical trials in patients with anemia associated to chronic kidney diseases are also scheduled to commence shortly. About chemotherapy-induced anemia ("CIA") Anemia is one of the most serious side effects caused by chemotherapy. Anemia is a condition in which red blood cells and hemoglobin are below normal levels. CIA is associated with a reduced quality of life and possible compromised treatment outcomes. Of the estimated 1.3 million new patients that undergo chemotherapy annually in the U.S., it is believed that approximately two third of these patients will develop CIA. Certain types of chemotherapy regimens are associated with more frequent and severe anemia often leading to the patients requiring blood transfusions. The treatment with rhEPO is active in only 50-60 percent of CIA patients. Typical doses of rhEPO required to treat CIA patients are two- to three-fold higher than those used to treat anemia in dialysis patients. About ProMetic Life Sciences Inc. ProMetic Life Sciences Inc. ( is a biopharmaceutical company specialized in the research, development, manufacture and marketing of a variety of commercial applications derived from its proprietary Mimetic Ligand(TM) technology. This technology is used in large-scale purification of biologics and the elimination of pathogens. ProMetic is also active in therapeutic drug development with the mission to bring to market effective, innovative, lower cost, less toxic products for the treatment of hematology and cancer. Its drug discovery platform is focused on replacing complex, expensive proteins with synthetic "drug-like" protein mimetics. Headquartered in Montreal (Canada), ProMetic has R&D facilities in the U.K., the U.S. and Canada, manufacturing facilities in the U.K. and business development activities in the US, Europe, Asia and in the Middle-East. Forward Looking Statements This press release contains forward-looking statements about ProMetic's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, ProMetic's ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of ProMetic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations on page 21 of ProMetic's Annual Information Form for the year ended December 31, 2006, under the heading "Risk Factors". As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason. Contacts: ProMetic Life Sciences Inc. Pierre Laurin President and CEO +1-514-341-2115 ProMetic Life Sciences Inc. Anne Leduc Manager, Communications +1-514-341-2115 ext. 2234 Echoes Financial Network Inc. Dominic Sicotte +1-514-842-9551 Lippert / Heilshorn & Associates Bruce Voss +1-310-691-7100 Lippert / Heilshorn & Associates Kim Golodetz +1-212-838-3777